FLUZONE INTRADERMAL Rx
Generic Name and Formulations:
Trivalent inactivated "split virus" influenza vaccine (Types A and B); 0.1mL dose contains a total of 27mcg of influenza virus hemmagglutinin; formulation changes annually; susp for intradermal inj.
Sanofi Pasteur, Inc.
Indications for FLUZONE INTRADERMAL:
18–64yrs: One dose per year. 0.1mL intradermally in the region of the deltoid.
<18yrs: not recommended. Use Fluzone IM.
Allergy to egg proteins. Life-threatening reaction to any previous flu vaccine.
Use current formulation only. Guillain-Barre syndrome within 6 weeks of previous flu vaccine. Immunosuppressed. Have epinephrine inj (1:1000) available. Pregnancy (Cat.C for IM and High-Dose; Cat.B for Intradermal, Intradermal Quadrivalent). Nursing mothers.
Immunosuppressants: may get suboptimal response.
Local reactions (eg, pain, tenderness, swelling, erythema), malaise, headache, myalgia, irritability.
Fluzone, Fluzone Quadrivalent prefilled syringe (0.25mL, 0.5mL)—10; Single-dose vial (0.5mL)—10; Fluzone multi-dose vial (5mL)—1 (contains thimerosal); Fluzone High-Dose prefilled syringe (0.5mL)—10; Fluzone Intradermal, Fluzone Intradermal Quadrivalent single-dose prefilled microinjection system (0.1mL)—10
Endocrinology Advisor Articles
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Link Between Gestational Diabetes and Risk for CVD and Diabetes in Hispanic/Latina Population
- Clinical Characteristics Altering Risks and Benefits of Sulfonylureas and Thiazolidinedione Therapy in T2D
- 6 Factors Related to Inclusion in Health Care Workplace Identified
- Weight Gain After Quitting Smoking May Increase Risk for T2D